Novo Nordisk A/S Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case

Published: Jan 20, 2011

BAGSVæRD, DENMARK--(Marketwire - January 19, 2011) -

Company Announcement no 2 2011:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Further information:

Mike Rulis
Tel: (+45) 3079 3573
Email Contact

In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
Email Contact


Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
Email Contact

Jannick Lindegaard
Tel: (+45) 4442 4765
Email Contact

In North America:
Hans Rommer
Tel: (+1) 609 919 7937
Email Contact

Back to news